Logo image of LGTO

LEGATO MERGER CORP II (LGTO) Stock Fundamental Analysis

NASDAQ:LGTO - Nasdaq - US52473Y1047 - Common Stock - Currency: USD

8.94  +0.16 (+1.82%)

After market: 8.96 +0.02 (+0.22%)

Fundamental Rating

2

Overall LGTO gets a fundamental rating of 2 out of 10. We evaluated LGTO against 0 industry peers in the Unkown industry. LGTO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LGTO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LGTO was profitable.
In the past year LGTO has reported a negative cash flow from operations.
LGTO Yearly Net Income VS EBIT VS OCF VS FCFLGTO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 -100K -200K -300K -400K

1.2 Ratios

Industry RankSector Rank
ROA 0.1%
ROE 0.1%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LGTO Yearly ROA, ROE, ROICLGTO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 -0.01 -0.02 -0.03 -0.04 -0.05

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LGTO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LGTO Yearly Profit, Operating, Gross MarginsLGTO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021

More info and screens

6

2. Health

2.1 Basic Checks

There is no outstanding debt for LGTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LGTO Yearly Shares OutstandingLGTO Yearly Shares OutstandingYearly Shares Outstanding 2021 10M 20M 30M
LGTO Yearly Total Debt VS Total AssetsLGTO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 19.56 indicates that LGTO is not in any danger for bankruptcy at the moment.
There is no outstanding debt for LGTO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.56
ROIC/WACCN/A
WACCN/A
LGTO Yearly LT Debt VS Equity VS FCFLGTO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 0 50M 100M 150M 200M 250M

2.3 Liquidity

LGTO has a Current Ratio of 4.14. This indicates that LGTO is financially healthy and has no problem in meeting its short term obligations.
LGTO has a Quick Ratio of 4.14. This indicates that LGTO is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.14
Quick Ratio 4.14
LGTO Yearly Current Assets VS Current LiabilitesLGTO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 500K 1M 1.5M

More info and screens

1

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154941.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LGTO will show a very strong growth in Earnings Per Share. The EPS will grow by 554.07% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y24309.58%
EPS Next 2Y1604.11%
EPS Next 3Y554.07%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LGTO Yearly Revenue VS EstimatesLGTO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 500M 1B 1.5B 2B
LGTO Yearly EPS VS EstimatesLGTO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 0.2 0.4 0.6 0.8 1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 894.00 indicates a quite expensive valuation of LGTO.
Compared to an average S&P500 Price/Earnings ratio of 27.93, LGTO is valued quite expensively.
Based on the Price/Forward Earnings ratio of 8.04, the valuation of LGTO can be described as reasonable.
LGTO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 37.78.
Industry RankSector Rank
PE 894
Fwd PE 8.04
LGTO Price Earnings VS Forward Price EarningsLGTO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 200 400 600 800

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGTO Per share dataLGTO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LGTO's earnings are expected to grow with 554.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y1604.11%
EPS Next 3Y554.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LGTO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEGATO MERGER CORP II

NASDAQ:LGTO (2/14/2023, 8:19:14 PM)

After market: 8.96 +0.02 (+0.22%)

8.94

+0.16 (+1.82%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-14 2022-11-14/bmo
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners1.51%
Ins Owner Change0%
Market Cap321.04M
Analysts85
Price Target13.6 (52.13%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.91%
Min EPS beat(2)-95.91%
Max EPS beat(2)-95.91%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.56%
PT rev (3m)2.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-34.15%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-26.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-19.65%
Valuation
Industry RankSector Rank
PE 894
Fwd PE 8.04
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.18
P/tB 1.18
EV/EBITDA N/A
EPS(TTM)0.01
EY0.11%
EPS(NY)1.11
Fwd EY12.44%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS7.58
TBVpS7.58
PEG (NY)0.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.1%
ROE 0.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.14
Quick Ratio 4.14
Altman-Z 19.56
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%154941.82%
EPS Next Y24309.58%
EPS Next 2Y1604.11%
EPS Next 3Y554.07%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82227.9%
EBIT Next 3Y933.62%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A